Codexis Partners with Nitto Denko to Enhance Oligonucleotide Therapeutics Manufacturing Efficiency

Codexis Partners with Nitto Denko Avecia to Advance Oligonucleotide Therapeutics

Codexis, Inc., a frontrunner in enzymatic solutions for therapeutic manufacturing, announces a strategic partnership with Nitto Denko Avecia, Inc., a well-established contract development and manufacturing organization (CDMO) known for its specialization in oligonucleotide therapeutics. This collaboration begins with an evaluation agreement that allows Nitto Denko Avecia to assess Codexis' innovative ECO Synthesis® Manufacturing Platform. The platform is designed to revolutionize oligonucleotide synthesis by employing a flexible, enzyme-catalyzed method rather than relying on conventional solid-phase techniques, thus enhancing both scalability and sustainability.

The integration of Codexis' ECO Synthesis® Manufacturing Platform into Nitto Denko Avecia’s existing capabilities marks a significant advancement in the production of small interfering RNA (siRNA) therapeutics. Stephen Dilly, Chairman and CEO of Codexis, articulates the excitement surrounding this partnership, emphasizing its potential to broaden the reach of their groundbreaking technology through collaborations with leading industry players. This move aligns with Codexis' mission to redefine therapeutic development and manufacturing processes, positioning itself as a long-term partner committed to fostering progress within the healthcare ecosystem.

Tammy Cooper, President of Nitto Denko Avecia, echoes this sentiment, asserting their dedication to advancing next-generation manufacturing technologies that enhance the efficiency and quality of therapeutic development. With a robust infrastructure, including facilities in Milford, MA, and Cincinnati, OH, Nitto Denko Avecia has a solid history of manufacturing over 1,500 oligonucleotide sequences, catering to both preclinical and commercial applications. This collaboration underscores a crucial milestone for both companies as they aim to deliver high-quality therapeutic solutions that meet the increasing demands of partners and patients globally.

In addition to this partnership, Codexis continues to focus on leveraging its proprietary technology and scientific expertise to set new standards in therapeutic manufacturing. By prioritizing sustainability and efficiency, Codexis positions itself as a catalyst for change in an industry that increasingly values environmentally responsible practices.

This collaboration with Nitto Denko Avecia is not just a testament to Codexis' innovative capabilities but also reflects a broader industry trend toward more sustainable and scalable production methods in therapeutic development. The partnership is poised to significantly influence the way oligonucleotide therapeutics are manufactured, ultimately benefiting both patients and healthcare providers.